NCT01709942View on ClinicalTrials.gov

Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
PCOSOHSSINFERTILITY
Interventions
DRUG

degarelix (long acting GnRH antagonist)

20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration

DRUG

cetrorelix 0.25mg

0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml

Trial Locations (1)

00153

Cerm-Hungaria, Rome

All Listed Sponsors
lead

Centre for Endocrinology and Reproductive Medicine, Italy

NETWORK

NCT01709942 - Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS) | Biotech Hunter | Biotech Hunter